Petosemtamab binds EGFR to inhibit EGFR signaling (MAPK/PI3K), reducing proliferation. Its Fc-mediated ADCC/ADCP is directed toward LGR5+ cells; EGFR binding is not used as the cytotoxic trigger unless cells also co-express LGR5.